ENT surgery denied? We cite AAO-HNS, NCCN H&N, and the trial data they ignored.

Why ENT denials follow a predictable script

Otolaryngology procedures are some of the most-denied surgeries in the entire payer book. The reason is not clinical — it is structural. Sinus surgery sits adjacent to "balloon sinuplasty," which until 2005 was unproven; septoplasty sits adjacent to rhinoplasty, which is cosmetic; tonsillectomy is one of the most common pediatric procedures and therefore one of the most-audited; and the OSA surgical pathway (UPPP, Inspire, MMA) sits next to CPAP, which is cheaper. Insurers have built entire denial workflows around the question, "Was the medical pathway actually exhausted, or are we paying for a shortcut?"

The good news is that AAO-HNS publishes detailed, evidence-graded clinical practice guidelines for nearly every common ENT denial scenario, and most insurer policies cite those guidelines verbatim. The work of an ENT appeal is not invention — it is matching the chart documentation to the AAO-HNS or NCCN language the insurer already accepts.

The five denial categories you will actually see

Most ENT denials reduce to five rejections:

1. "Maximal medical therapy not documented" — for sinus surgery, this means INCS, saline, antibiotics, sometimes a steroid taper, all with dates and outcomes.

2. "Septoplasty appears cosmetic" — for septoplasty, this means functional symptoms (NOSE score, endoscopic obstruction) need to be documented separately from any rhinoplasty intent.

3. "Paradise criteria not met" — for tonsillectomy, the threshold is well-known and very specific: 7 in one year, 5/year for two years, or 3/year for three years.

4. "Try CPAP first" — for any OSA surgery (UPPP, Inspire, MMA), this means a documented PAP failure or intolerance with adherence data.

5. "Try chemoradiation first" — for head and neck cancer surgery, this means the tumor board has to have ruled on modality selection in writing.

Each of these has a precise AAO-HNS or NCCN counter, and the appeal letter writes itself once the chart is complete.

Sinus surgery: the AAO-HNS Adult Sinusitis 2015 framework

The 2015 update of the AAO-HNS Clinical Practice Guideline on Adult Sinusitis (Rosenfeld, Otolaryngol Head Neck Surg 2015;152(2 Suppl):S1–S39) is the single most-cited document in any FESS appeal. It defines chronic rhinosinusitis (CRS) as ≥12 weeks of two or more cardinal symptoms (nasal obstruction, anterior or posterior drainage, facial pain/pressure, hyposmia) plus objective evidence on nasal endoscopy or CT. That last requirement — objective evidence — is what insurers focus on.

A successful FESS appeal includes:

• The CT sinus report with an explicit Lund-Mackay score (most policies want ≥8; some want ≥12) and explicit description of osteomeatal complex obstruction, mucosal thickening, polyps, or anatomic variants.
• The nasal endoscopy report with Lund-Kennedy score, polyp grade if present, and mucopurulent drainage if present.
• The medical therapy log: intranasal corticosteroid (usually fluticasone or mometasone) for at least four weeks of continuous use, saline irrigation, an antibiotic course for any acute exacerbation, and (in some cases) a short oral steroid taper for polyposis.
• For polyposis specifically, document whether the patient has tried or qualifies for a biologic (dupilumab, omalizumab, mepolizumab) per ICAR-RS 2021 — and if so, why surgery is being chosen first or instead.

For balloon sinus ostial dilation specifically, cite the AAO-HNS Position Statement on Balloon Sinus Ostial Dilation, which supports its use in selected uncomplicated CRS without polyposis. The REMODEL randomized trial (Bikhazi 2014) and others provide the comparative-effectiveness data.

Septoplasty: separating function from cosmetics

Septoplasty denials almost always carry the word "cosmetic." The defense is to document functional obstruction and keep it separate from any rhinoplasty discussion.

The cleanest septoplasty appeal includes:

• A NOSE (Nasal Obstruction Symptom Evaluation) score above 50 — this is a validated patient-reported outcome measure and most insurer policies recognize it.
• An anterior rhinoscopy or nasal endoscopy report describing which side of the septum is deviated, the degree, and what specifically is being obstructed (caudal versus posterior, contact with turbinate, etc.).
• A CT or photograph confirming the deviation if the obstruction is unclear from exam alone.
• Documentation of failed medical therapy (INCS, saline) for at least 4–6 weeks, since some policies require a medical-therapy trial even for purely structural disease.
• An explicit functional indication ("symptomatic nasal obstruction refractory to medical therapy"), not a cosmetic one.

Cite the AAO-HNS Septoplasty Improvement Criteria (Rhee Otolaryngol Head Neck Surg 2010) and Aetna's own CPB 0257, which lists these elements specifically. When septoplasty is performed alongside cosmetic rhinoplasty, separate the documentation cleanly so the functional component reads as independently medically necessary.

Inferior turbinate reduction: a procedural addendum, not a standalone

Insurers tend not to deny inferior turbinate reduction when it is performed alongside septoplasty for combined obstruction. They tend to deny it when it is a standalone procedure for "rhinitis." The defense is to document hypertrophy on endoscopy or CT, failed medical therapy specifically targeting the turbinates (INCS, antihistamine, ipratropium), and the type of reduction (submucous resection preserves mucosa and is preferred over total turbinectomy, which carries empty-nose-syndrome risk).

Tonsillectomy and adenoidectomy: Paradise criteria are non-negotiable

The 2019 AAO-HNS Clinical Practice Guideline on Tonsillectomy in Children (Mitchell, Otolaryngol Head Neck Surg 2019;160(1 Suppl):S1–S42) is the controlling document. It endorses the Paradise criteria (Paradise NEJM 1984) for recurrent throat infection: ≥7 episodes in one year, ≥5 per year for two years, or ≥3 per year for three years, with documented diagnosis (clinical + ideally culture or rapid antigen test).

A successful tonsillectomy appeal includes:

• A chronological infection log with date of visit, clinician, examination findings (tonsillar exudate, cervical lymphadenopathy, fever), positive strep culture or rapid test where applicable, antibiotic prescribed, and resolution.
• For pediatric sleep-disordered breathing, the AAO-HNS guideline supports T&A as first-line for adenotonsillar hypertrophy with documented OSA on PSG. For uncomplicated cases, clinical assessment plus tonsillar grade may suffice; for complicated cases (obese, age <2, comorbidities) PSG is required.
• For PFAPA syndrome (periodic fever, aphthous stomatitis, pharyngitis, adenitis), the diagnostic criteria are well-defined and tonsillectomy is curative in a majority — submit a pediatrician or rheumatology note confirming diagnosis.
• For peritonsillar abscess history, document at least one event with the surgical specimen or imaging, plus recurrent infection if relevant.

Adenoidectomy alone (without tonsillectomy) is generally covered for chronic adenoiditis, recurrent otitis media (with tubes), or nasal obstruction from adenoid hypertrophy on lateral neck radiograph or nasopharyngoscopy.

OSA surgery: PAP failure is the gatekeeper

For any surgical OSA pathway — UPPP, expansion sphincter pharyngoplasty, hypoglossal nerve stimulation (Inspire), or maxillomandibular advancement — the denial almost always says "try CPAP first." If CPAP has been tried, the documentation needs to show it.

The defensible PAP-failure file contains:

• The diagnostic PSG with AHI severity, nadir SpO2, supine AHI if available.
• A titration study or APAP cloud data showing pressure setting.
• 90 days of adherence data from the PAP cloud (ResMed AirView, Philips Encore Anywhere, etc.) — usage hours per night, percentage of nights used ≥4 hours, residual AHI on therapy, leak data.
• Documentation of mask trials (full-face, nasal, nasal pillow), mode trials (CPAP → APAP → BiPAP), pressure-tolerance issues, claustrophobia, skin breakdown, or other reasons for discontinuation.
• A clinician note explicitly stating "PAP failure / intolerance per AASM definition."

For Inspire hypoglossal nerve stimulator specifically, the additional requirements are codified in the CMS LCD framework that nearly all commercial insurers mirror:

• AHI between 15 and 65 historically (the 2023/2024 FDA labeling expansion brought this to 100, and insurer policies are catching up).
• BMI typically <32 historically, now often <40 reflecting the expanded label.
• Age ≥18 (≥13 for the recent pediatric expansion in Down syndrome).
• DISE (drug-induced sleep endoscopy) showing no complete concentric palatal collapse — this is a hard exclusion.
• Central apnea index <25%.

Cite the STAR trial (Strollo NEJM 2014;370:139–49) for the pivotal RCT, the 5-year follow-up (Woodson Otolaryngol Head Neck Surg 2018), and the ADHERE registry (Heiser Eur Respir J 2020; Suurna Otolaryngol HNS 2021) for real-world adherence and AHI reduction. Cite the FDA PMA P130008 and the 2023/2024 supplemental labeling for the indication expansion.

For UPPP, cite the AAO-HNS OSA surgery position statement and document why this patient is anatomically appropriate (Friedman tongue position, palate-tonsil grade). For MMA, cite the meta-analyses of MMA versus CPAP and the AHI-reduction data.

Otologic surgery: tympanoplasty, stapedectomy, mastoidectomy

These tend to be lower-volume denials, but when they happen, the defense is straightforward.

For tympanoplasty, submit the audiogram with pure-tone average, air-bone gap, and word recognition score; the otoscopy or otomicroscopy finding documenting persistent perforation; failed conservative management (water precautions, dry ear care, treatment of middle-ear infection); and the AAO-HNS reference for chronic otitis media.

For stapedectomy / stapedotomy in otosclerosis, submit the audiogram with characteristic conductive or mixed hearing loss and Carhart's notch at 2 kHz; tympanometry; absent or atypical stapedial reflexes; and a discussion of hearing-aid alternatives. Cite the AAO-HNS positions on otosclerosis.

For mastoidectomy for cholesteatoma or chronic suppurative otitis media, the CT temporal bone is the central document — it must describe scutum erosion, ossicular chain status, attic / mesotympanum disease, labyrinthine fistula if present. Otomicroscopy showing keratin debris in a retraction pocket or attic also supports the diagnosis. Note that for cochlear-related procedures excluding the cochlear implant itself (which lives under the hearing-aids vertical), the rationale is similar — audiogram + imaging + functional impact.

Head and neck cancer surgery: NCCN and the tumor board

When an insurer denies a laryngectomy, neck dissection, TORS, thyroidectomy, parotidectomy, or other head and neck oncologic procedure, the denial almost always cites either "experimental" (for newer modalities) or "try chemoradiation first." The single most powerful counter is a tumor board note.

A successful head and neck cancer appeal includes:

• The pathology report with ICD-10 oncologic diagnosis, AJCC 8th edition T/N/M stage, and (for oropharyngeal SCC) p16 / HPV status.
• The PET-CT or staging imaging with explicit measurements (primary tumor size, nodal size, distant disease assessment).
• A multidisciplinary tumor board note explicitly documenting that the case was reviewed by head and neck surgery, radiation oncology, and medical oncology, with the recommended modality and rationale.
• The NCCN Head and Neck Cancers Guideline reference for the specific subsite (oral cavity, oropharynx, larynx, hypopharynx, salivary, thyroid, paranasal sinus, occult primary).

For TORS specifically, cite ECOG 3311 (Ferris JCO 2022) supporting TORS plus risk-adapted adjuvant therapy for HPV-positive oropharyngeal SCC. The de-intensification trials (TROG 02.02, De-ESCALaTE) provide additional context for surgical-primary modality selection in p16+ disease. Document surgeon credentialing for TORS and the FDA-cleared robotic platform (typically da Vinci, FDA cleared for TORS in 2009).

For laryngectomy, the defense usually involves discussing why organ preservation with concurrent chemoradiation (RTOG 91-11, Forastiere NEJM 2003 / JCO 2013) is contraindicated for this specific patient — large T3-T4 tumor with cartilage invasion, prior RT failure, dysfunctional larynx, or patient preference after counseling. Cite the VA Larynx Trial (Wolf NEJM 1991) for the original organ-preservation principles and the post-RTOG 91-11 long-term data showing local control comparable but with significant late toxicity.

For thyroidectomy, cite the 2015 American Thyroid Association Guidelines for Differentiated Thyroid Cancer (Haugen Thyroid 2015). For indeterminate Bethesda categories III and IV, document molecular testing (Afirma, ThyroSeq) results when available. For lobectomy versus total thyroidectomy, the ATA risk-stratification supports lobectomy for many <4cm low-risk cancers, which insurers actually prefer because it is less invasive.

Voice and laryngology procedures

Microlaryngoscopy with vocal fold surgery (polyp, cyst, leukoplakia, recurrent respiratory papillomatosis) and vocal fold medialization (Type I thyroplasty or injection laryngoplasty) are rarely denied outright but occasionally face "documentation insufficient" denials. The defense is the stroboscopy report and a quantitative voice handicap measure.

A successful laryngology appeal includes:

• Stroboscopy or videolaryngoscopy report describing the lesion, vocal fold mobility, mucosal wave, and glottic closure.
• The Voice Handicap Index (VHI-10 or VHI-30) score — most insurer policies recognize this as a validated patient-reported outcome.
• For dysphonia, the AAO-HNS Hoarseness/Dysphonia Update (Stachler Otolaryngol Head Neck Surg 2018) provides the diagnostic and management framework.
• For vocal fold paralysis with aspiration, document swallow study findings and the patient's voice and swallowing impact.

The peer-to-peer call: same-specialty matters

Most ENT denials carry a 14-day window for a peer-to-peer review. Demand it explicitly in the appeal letter and insist on a same-specialty reviewer — an otolaryngologist, not a generalist. For head and neck cancer cases, request a head and neck surgical oncologist specifically. For Inspire denials, request a sleep surgeon. The peer-to-peer rules:

• Bring three things to the call: the imaging or PSG measurements, the medical-therapy log, and the specific guideline citation that the insurer's own policy mirrors.
• Document the call in writing afterward — date, time, the medical director's name, the points discussed, and the outcome.
• Most overturn-on-peer-to-peer outcomes happen when the calling otolaryngologist can quote the AAO-HNS guideline language back to the medical director.

A note on letter length and structure

An ENT appeal should be 1.5 to 2 pages. The structure that works:

1. Header with member ID, claim number, procedure, CPT.

2. Diagnosis with ICD-10, duration, and the imaging/endoscopy/PSG/audiogram measurement that anchors the case (one paragraph).

3. Medical therapy log — concise but complete.

4. Address the denial directly — quote the insurer's own coverage criteria, demonstrate each is met, cite the controlling AAO-HNS CPG / NCCN / pivotal trial.

5. For oncologic cases, a tumor-board note paragraph.

6. Closing — request overturn within deadline, demand peer-to-peer with same-specialty reviewer.

The medical director responds to evidence and policy citations, not adjectives. Avoid emotional language; let the Lund-Mackay score, the AHI, the NOSE score, the AJCC stage, and the AAO-HNS reference do the work.

When to escalate

If the first-level appeal fails, the next steps depend on plan type. Self-funded ERISA plans go to second-level internal review and then to external review under ACA §2719. Fully-insured state-regulated plans go to state external review through the state insurance department. Medicare Advantage cases route through the Independent Review Entity and then the ALJ hearing. Medicaid follows the state Fair Hearing process. Each level has its own deadlines (typically 60–180 days from the prior denial), and a well-organized otolaryngology practice keeps the timer running on all of them.

Most ENT denials reverse on first appeal when the AAO-HNS guideline is cited, the chart documentation matches the policy criteria, and the peer-to-peer is requested. The work is in the documentation — once the chart contains the right measurements and the right references, drafting the letter is mechanical.